ArticlePloS one2016
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 76 citations in OpenAlex.
- Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.American journal of physiology. Renal physiology · 2018Trial
- Empagliflozin does not prevent progression of Dent's disease type 1 in a mouse model.Experimental physiology · 2026Article
- The Effect of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats.Biomedicines · 2025Article
- SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection?Journal of clinical medicine · 2025Review
- Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice.Physiological reports · 2025Article
- Crosstalk between glomeruli and tubules.Nature reviews. Nephrology · 2025Review
- Canagliflozin alleviates acetaminophen-induced renal and hepatic injury in mice by modulating the p-GSK3β/Fyn-kinase/Nrf-2 and p-AMPK-α/STAT-3/SOCS-3 pathways.Scientific reports · 2025Article
- Sodium glucose transporter 2 inhibitors: Will these drugs benefit non-diabetic veterinary patients with cardiac and kidney diseases?Journal of veterinary pharmacology and therapeutics · 2025Review
- Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases.Physiological research · 2024Review
- Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side.Journal of clinical medicine · 2024Review
- Canagliflozin protects the cardiovascular system through effects on the gut environment in non-diabetic nephrectomized rats.Clinical and experimental nephrology · 2023Article
- Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system.American journal of physiology. Cell physiology · 2023Article
- Review
- Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats.Journal of translational medicine · 2022Article
- Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease.Biomedicines · 2022Article
- Renal outcomes with sodium-glucose cotransporters 2 inhibitors.Frontiers in endocrinology · 2022Review
- Review
- Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.Acta diabetologica · 2021Article
- Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pharmacological inhibition of the proximal tubular sodium-glucose linked cotransporter-2 (SGLT2) leads to glycosuria in both diabetic and non-diabetic settings. As a consequence of their ability to modulate tubuloglomerular feedback, SGLT2 inhibitors, like agents that block the renin-angiotensin system, reduce intraglomerular pressure and single nephron GFR, potentially affording renoprotection. To examine this further we administered the SGLT2 inhibitor, dapagliflozin, to 5/6 (subtotally) nephrectomised rats, a model of progressive chronic kidney disease (CKD) that like CKD in humans is characterised by single nephron hyperfiltration and intraglomerular hypertension and where angiotensin converting enzyme inhibitors and angiotensin receptor blockers are demonstrably beneficial. When compared with untreated rats, both sham surgery and 5/6 nephrectomised rats that had received dapagliflozin experienced substantial glycosuria. Nephrectomised rats developed hypertension, heavy proteinuria and declining GFR that was unaffected by the administration of dapagliflozin. Similarly, SGLT2 inhibition did not attenuate the extent of glomerulosclerosis, tubulointerstitial fibrosis or overexpression of the profibrotic cytokine, transforming growth factor-ß1 mRNA in the kidneys of 5/6 nephrectomised rats. While not precluding beneficial effects in the diabetic setting, these findings indicate that SGLT2 inhibition does not have renoprotective effects in this classical model of progressive non-diabetic CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.